Skip to content
IDesia logo — Harnessing Heartbeats for Secure Authentication and Enhanced...

IDesia

Harnessing Heartbeats for Secure Authentication and Enhanced Health Insights

Founded 2004 Series A Biotechnology, Health Care +2

General Information

Company Name IDesia
Founded Year 2004
Industries Biotechnology, Health Care, Information Technology +1
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with IDesia. To contact IDesia, visit idesia-biometrics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IDesia compare?

A PDF of IDesia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IDesia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IDesia

IDesia is a medical device company that specializes in BioDynamic Signature authentication technology and products, with a slogan of "Harnessing Heartbeats for Secure Authentication and Enhanced Health Insights". The company was founded in 2004 and is headquartered in Caesarea, Israel. IDesia's technology leverages heartbeats to identify users on PCs, mobile devices, and other gadgets, while also providing valuable health insights. In addition to biometric authentication, the company's focus extends to personal health, fitness, and well-being. Its unique technology assigns an electro biodynamic signature to every heartbeat, making it nearly impossible to forge. The company received its Series A investment on 02 December 2005, with the investment coming from Partech. With its innovative approach at the nexus of biotechnology, health care, information technology, and mobile industries, IDesia has the potential to revolutionize secure authentication and health monitoring.

Business keywords: medical device company, biometric authentication, BioDynamic Signature technology, health insights, heartbeats authentication, personal health, fitness technology, well-being technology, electro biodynamic signature, forgery-proof technology, Israel based company

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Partech
02 Dec 2005

IDesia Alternatives & Competitors

View All Alternatives
IDesia vs

Right exercise, right results!

6 employees
Consumer Goods, Information Technology
IDesia vs

Achieve mental wellness with reliable tools that measure, monitor, and enhance your brain activity f...

Grant
Health Care, Mobile
IDesia vs

Empowering you to address life's challenges effortlessly, ensuring a journey towards health, happine...

Seed
1 employees
Health Care, Mobile

FAQ About IDesia

Harnessing Heartbeats for Secure Authentication and Enhanced Health Insights
IDesia was founded in 2004.
IDesia operates in Biotechnology, Health Care, Information Technology and Mobile. Its work centres on medical device company, biometric authentication, BioDynamic Signature technology and health insights.
IDesia has completed 1 funding round. The latest funding stage is Series A.
Top alternatives and competitors to IDesia include LightWeight, Cortechs, Oceen, SureSafe Personal Alarms, Bloomer Tech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IDesia and LightWeight are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IDesia, https://www.bouncewatch.com/company/idesia, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout